ROCKVILLE, Md., Dec. 1,
2016 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT:
SYN), a late-stage clinical company developing therapeutics focused
on the gut microbiome, today announced that members of Synthetic
Biologics' executive leadership team will participate in two
upcoming investor conferences:
2016 Jefferies Annual Microbiome Summit
London, England
Tuesday, December 13, 2016
Guggenheim Securities 4th Annual Boston Healthcare
Conference
Boston, MA
Tuesday, December 13, 2016
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a late-stage
clinical company developing therapeutics focused on the gut
microbiome. The Company's lead candidates poised for Phase 3
development are: (1) SYN-010 which is intended to reduce the impact
of methane producing organisms in the gut microbiome to treat an
underlying cause of irritable bowel syndrome with constipation
(IBS-C), and (2) SYN-004 (ribaxamase) which is designed to protect
the gut microbiome from the effects of certain commonly used
intravenous (IV) beta-lactam antibiotics for the prevention of C.
difficile infection, antibiotic-associated diarrhea (AAD) and the
emergence of antibiotic-resistant organisms. The Company is also
developing preclinical stage monoclonal antibody therapies for the
prevention and treatment of pertussis and novel discovery stage
biotherapeutics for the treatment of phenylketonuria (PKU). For
more information, please visit Synthetic Biologics' website at
www.syntheticbiologics.com.
Logo - http://photos.prnewswire.com/prnh/20160105/319502LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/synthetic-biologics-announces-participation-in-two-upcoming-investor-conferences-300370677.html
SOURCE Synthetic Biologics, Inc.